Twist Bioscience (NASDAQ:TWST) Stock: Insider Robert Werner Sells 148 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 148 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $20,039.20. Following the completion of the transaction, the chief accounting officer owned 42,769 shares of the company’s stock, valued at approximately $5,790,922.60. This trade represents a 0.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $120.79 on Friday. The company has a market cap of $7.57 billion, a PE ratio of -54.41 and a beta of 2.25. The stock has a fifty day moving average price of $151.35 and a 200 day moving average price of $91.08. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience News Roundup

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Root Financial Partners LLC acquired a new stake in shares of Twist Bioscience in the third quarter worth about $33,000. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 94.3% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock worth $106,000 after buying an additional 266 shares during the last quarter. Allworth Financial LP purchased a new position in Twist Bioscience in the 2nd quarter worth $62,000. Trifecta Capital Advisors LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $63,000. Finally, Western Wealth Management LLC bought a new stake in shares of Twist Bioscience during the first quarter valued at approximately $31,000.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TWST. Robert W. Baird upped their price target on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. BWS Financial restated a “sell” rating and issued a $45.00 price objective on shares of Twist Bioscience in a research note on Friday, September 18th. Barclays increased their target price on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Finally, Piper Sandler upped their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $153.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.